Search

Your search keyword '"Losonczy, G."' showing total 344 results
Start Over Author "Losonczy, G." Publication Year Range Last 50 years
344 results on '"Losonczy, G."'

1. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Author

Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M.J., Özgüroğlu, M., Ji, J.H., Garassino, M.C., Voitko, O., Poltoratskiy, A., Musso, E., Havel, L., Bondarenko, I., Losonczy, G., Conev, N., Mann, H., Dalvi, T.B., Jiang, H., and Goldman, J.W.

Published
2022
Full Text
View/download PDF

2. OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results

Author

Liu, S.V., primary, Dziadziuszko, R., additional, Sugawara, S., additional, Kao, S., additional, Hochmair, M., additional, Huemer, F., additional, Castro, G., additional, Havel, L., additional, Caro, R.B., additional, Losonczy, G., additional, Lee, J.-S., additional, Kowalski, D., additional, Andric, Z., additional, Califano, R., additional, Veatch, A., additional, Gerstner, G., additional, Batus, M., additional, Morris, S., additional, Kaul, M., additional, Siddiqui, M., additional, Li, H., additional, Zhang, W., additional, Nabet, B., additional, and Reck, M., additional

Published
2023
Full Text
View/download PDF

3. 1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN

Author

Reinmuth, N., primary, Goldman, J.W., additional, Chen, Y., additional, Hotta, K., additional, Statsenko, G., additional, Hochmair, M.J., additional, Özgüroğlu, M., additional, Ji, J.H., additional, Garassino, M.C., additional, Poltoratskiy, A., additional, Verderame, F., additional, Havel, L., additional, Bondarenko, I., additional, Losonczy, G., additional, Conev, N.V., additional, Mann, H., additional, Chugh, P., additional, Dalvi, T.B., additional, and Paz-Ares, L., additional

Published
2022
Full Text
View/download PDF

4. Nivolumab-Induced Ulcerative Keratitis-A Case Report

Author

Losonczy, G., Losonczy, G., Gijs, M., Nuijts, R.M.M.A., Losonczy, G., Losonczy, G., Gijs, M., and Nuijts, R.M.M.A.

Abstract

Purpose: To describe a case of nivolumab-induced ulcerative keratitis rapidly recovering on topical steroid treatment and to determine changes in cytokine levels in the tear fluid caused by nivolumab. Methods: We report a 34-year-old man receiving nivolumab for metastasized melanoma with severe dry eye symptoms and a persistent corneal epithelial defect. Levels of cytokine and matrix metalloproteinase in tear fluid were measured by multiplex immunoassays. Results: The corneal epithelial defect failed to recover for antiviral and lubrication therapy but resolved within 48 hours after topical steroid therapy was initiated. No recurrence of corneal ulceration was observed with intermittent topical steroid therapy during the remaining period of nivolumab treatment. No Sjogren disease-related autoantibodies were detected in the patient's serum. The levels of inflammatory cytokines and matrix metalloproteinases in the tear fluid were markedly elevated after nivolumab treatment. Conclusions: Our observations suggest that nivolumab treatment induces a local autoimmune ocular surface disorder resulting in corneal ulceration that promptly resolves using steroid eye drops. The integrity of the corneal epithelial layer can be sustained using intermittent topical steroid therapy in patients receiving nivolumab.

Published
2021

5. Durvalumab+ Tremelimumab + Platin-Etoposide in first-line extensive-stage SCLC (ES-SCLC): 36-month Overall Survival from the Phase 3 CASPIAN study

Author

Bischoff, H, additional, Paz-Ares, L, additional, Chen, Y, additional, Reinmuth, N, additional, Hotta, K, additional, Trukhin, D, additional, Statsenko, G, additional, Hochmair, M J, additional, Özgüroğlu, M, additional, Li, J H, additional, Voitko, O, additional, Poltoratskiy, A, additional, Verderame, F, additional, Havel, L, additional, Bondarenko, I, additional, Losonczy, G, additional, Conev, N, additional, Broadhurst, H, additional, Dalvi, T, additional, Jiang, H, additional, Golgman, J W, additional, and Alt, J, additional

Published
2022
Full Text
View/download PDF

8. LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

Author

Paz-Ares, L., primary, Chen, Y., additional, Reinmuth, N., additional, Hotta, K., additional, Trukhin, D., additional, Statsenko, G., additional, Hochmair, M.J., additional, Ozguroglu, M., additional, Ji, J.H., additional, Voitko, O., additional, Poltoratskiy, A., additional, Verderame, F., additional, Havel, L., additional, Bondarenko, I., additional, Losonczy, G., additional, Conev, N.V., additional, Broadhurst, H.L., additional, Dalvi, T., additional, Jiang, H., additional, and Goldman, J.W., additional

Published
2021
Full Text
View/download PDF

10. Clinical relevance is associated with allergen-specific wheal size in skin prick testing

Author

Haahtela, T., Burbach, G. J., Bachert, C., Bindslev-Jensen, C., Bonini, S., Bousquet, J., Bousquet-Rouanet, L., Bousquet, P. J., Bresciani, M., Bruno, A., Canonica, G. W., Darsow, U., Demoly, P., Durham, S. R., Fokkens, W. J., Giavi, S., Gjomarkaj, M., Gramiccioni, C., Kowalski, M. L., Losonczy, G., Orosz, M., Papadopoulos, N. G., Stingl, G., Todo-Bom, A., von Mutius, E., Köhli, A., Wöhrl, S., Järvenpää, S., Kautiainen, H., Petman, L., Selroos, O., Zuberbier, T., and Heinzerling, L. M.

Published
2014
Full Text
View/download PDF

11. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

Author

Distler, O, Highland, Kb, Gahlemann, M, Azuma, A, Fischer, A, Mayes, Md, Raghu, G, Sauter, W, Girard, M, Alves, M, Clerisme-Beaty, E, Stowasser, S, Tetzlaff, K, Kuwana, M, Maher, Tm, Bergna, M, Casado, G, Mannucci Walter, P, Proudman, S, Stevens, W, Thakkar, V, Troy, L, Loeffler-Ragg, J, Olschewski, H, Bondue, B, Houssiau, F, Smith, V, Wuyts, W, Johnson, S, Keystone, E, Khalidi, N, Levesque, M, Maturana Rozas, R, Silva Orellana, A, Huang, C, Li, J, Jiang, Z, Liu, Y, Xiao, W, Xu, J, Zeng, X, Zheng, Y, Zou, H, Becvar, R, Madsen, H, Søndergaard, K, Kilpeläinen, M, Myllärniemi, M, Agard, C, Allanore, Y, Bourdin, A, Cottin, V, Crestani, B, Diot, E, Dominique, S, Hachulla, E, Jouneau, S, Leroy, S, Nunes, H, Prevot, G, Wallaert, B, Wemeau, L, Aringer, M, Bewig, B, Blaas, S, Distler, J, Ehrchen, J, Ewert, R, Gläser, S, Henes, J, Hunzelmann, N, König, R, Kötter, I, Kreuter, M, Prasse, A, Schulze-Koops, H, Sfikakis, P, Vlachoyiannopoulos, P, Losonczy, G, Behera, D, Gayathri Devi HJ, Kadel, J, Kawedia, M, Kumar, D, Kumar, U, Lokhande, R, Malpani, A, Mohan, M, Nalawade, A, Parakh, U, Swarnakar, R, Shobha, V, Thangakunam, B, Udwadia, Z, Henry, M, O'Reilly, K, Balbir-Gurman, A, Kramer, M, Litinsky, I, Rosner, I, Cutolo, M, Gabrielli, A, Iaccarino, L, Pesci, A, Riccieri, V, Vettori, S, Funakubo, Y, Inoue, Y, Kawakami, A, Kawaguchi, Y, Kawamura, T, Kondoh, Y, Nanki, T, Nishioka, Y, Nozawa, K, Oguragawa, T, Okamoto, M, Sano, H, Sasai, R, Sasaki, N, Suda, T, Takahashi, H, Takeuchi, T, Tanaka, S, Yamasaki, Y, Ch'Ng, Ss, Cheah, C, Kan, S, Raja Mohamed RB, Selman, M, de Vries-Bouwstra JK, van den Toorn, L, Vonken, M, Voskuyl, Ae, Hoffmann-Vold, Am, Seip, M, Dankiewicz-Fares, I, Olesiejuk, R, Pulka, G, Szepietowski, J, Alves, J, Bernardes, M, Cordeiro, A, Costa, J, Neves, S, Salvador, Mj, Alegre Sancho, J, Carreira Delgado, P, Castellví Barranco, I, Cifrián Martínez, J, Guillén Del Castillo, A, Ovalles, Jg, López-Longo, Fj, Rivera Gallego, A, Freire Dapena MC, Román Ivorra JA, Ekwall, Ah, Maurer, B, Mihai, Cm, Müller, R, Mahakkanukrauh, A, Nantiruj, K, Siripaitoon, B, Denton, Cp, Herrick, A, Madhok, R, West, A, Bascom, R, Criner, G, Csuka, Me, Dematte D'Amico, J, Ettinger, N, Gerbino, A, Gerke, A, Glassberg, M, Glazer, C, Golden, J, Gripaldo, R, Gupta, N, Hamblin, M, Highland, K, Ho, L, Huggins, Jt, Hummers, L, Jones, L, Kahaleh, M, Khanna, D, Kim, H, Lancaster, Lh, Luckhardt, T, Mayes, M, Mendoza Ballesteros, F, Mooney, J, Mohabir, P, Morrissey, B, Moua, T, Padilla, M, Patel, N, Perez, R, Roman, J, Rossman, M, Russell, T, Saketkoo, L, Shah, A, Shlobin, O, Scholand, Mb, Simmssetts, R, Spiera, R, Steen, V, Veeraraghavan, S, Weigt, S., Distler, O, Highland, Kb, Gahlemann, M, Azuma, A, Fischer, A, Mayes, Md, Raghu, G, Sauter, W, Girard, M, Alves, M, Clerisme-Beaty, E, Stowasser, S, Tetzlaff, K, Kuwana, M, Maher, Tm, SENSCIS Trial Investigators., Bergna M, Casado, G, Mannucci Walter, P, Proudman, S, Stevens, W, Thakkar, V, Troy, L, Loeffler-Ragg, J, Olschewski, H, Bondue, B, Houssiau, F, Smith, V, Wuyts, W, Johnson, S, Keystone, E, Khalidi, N, Levesque, M, Maturana Rozas, R, Silva Orellana, A, Huang, C, Li, J, Jiang, Z, Liu, Y, Xiao, W, Xu, J, Zeng, X, Zheng, Y, Zou, H, Becvar, R, Madsen, H, Søndergaard, K, Kilpeläinen, M, Myllärniemi, M, Agard, C, Allanore, Y, Bourdin, A, Cottin, V, Crestani, B, Diot, E, Dominique, S, Hachulla, E, Jouneau, S, Leroy, S, Nunes, H, Prevot, G, Wallaert, B, Wemeau, L, Aringer, M, Bewig, B, Blaas, S, Distler, J, Ehrchen, J, Ewert, R, Gläser, S, Henes, J, Hunzelmann, N, König, R, Kötter, I, Kreuter, M, Prasse, A, Schulze-Koops, H, Sfikakis, P, Vlachoyiannopoulos, P, Losonczy, G, Behera, D, Gayathri Devi, Hj, Kadel, J, Kawedia, M, Kumar, D, Kumar, U, Lokhande, R, Malpani, A, Mohan, M, Nalawade, A, Parakh, U, Swarnakar, R, Shobha, V, Thangakunam, B, Udwadia, Z, Henry, M, O'Reilly, K, Balbir-Gurman, A, Kramer, M, Litinsky, I, Rosner, I, Cutolo, M, Gabrielli, A, Iaccarino, Laura, Pesci, A, Riccieri, V, Vettori, S, Funakubo, Y, Inoue, Y, Kawakami, A, Kawaguchi, Y, Kawamura, T, Kondoh, Y, Nanki, T, Nishioka, Y, Nozawa, K, Oguragawa, T, Okamoto, M, Sano, H, Sasai, R, Sasaki, N, Suda, T, Takahashi, H, Takeuchi, T, Tanaka, S, Yamasaki, Y, Ch'Ng, S, Cheah, C, Kan, S, Raja Mohamed, Rb, Selman, M, de Vries-Bouwstra, Jk, van den Toorn, L, Vonken, M, Voskuyl, Ae, Hoffmann-Vold, Am, Seip, M, Dankiewicz-Fares, I, Olesiejuk, R, Pulka, G, Szepietowski, J, Alves, J, Bernardes, M, Cordeiro, A, Costa, J, Neves, S, Salvador, Mj, Alegre Sancho, J, Carreira Delgado, P, Castellví Barranco, I, Cifrián Martínez, J, Guillén Del Castillo, A, Ovalles, Jg, López-Longo, Fj, Rivera Gallego, A, Freire Dapena, Mc, Román Ivorra, Ja, Ekwall, Ah, Maurer, B, Mihai, Cm, Müller, R, Mahakkanukrauh, A, Nantiruj, K, Siripaitoon, B, Denton, Cp, Herrick, A, Madhok, R, West, A, Bascom, R, Criner, G, Csuka, Me, Dematte D'Amico, J, Ettinger, N, Gerbino, A, Gerke, A, Glassberg, M, Glazer, C, Golden, J, Gripaldo, R, Gupta, N, Hamblin, M, Highland, K, Ho, L, Huggins, Jt, Hummers, L, Jones, L, Kahaleh, M, Khanna, D, Kim, H, Lancaster, Lh, Luckhardt, T, Mayes, M, Mendoza Ballesteros, F, Mooney, J, Mohabir, P, Morrissey, B, Moua, T, Padilla, M, Patel, N, Perez, R, Roman, J, Rossman, M, Russell, T, Saketkoo, L, Shah, A, Shlobin, O, Scholand, Mb, Simmssetts, R, Spiera, R, Steen, V, Veeraraghavan, S, Weigt, S., National Institute for Health Research, British Lung Foundation, University of Zurich, and Distler, Oliver

Subjects
Male, Vital capacity, Indoles, Vital Capacity, Administration, Oral, 2700 General Medicine, 030204 cardiovascular system & hematology, Pulmonary function testing, law.invention, oral, Idiopathic pulmonary fibrosis, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, SENSCIS Trial Investigators, CYCLOPHOSPHAMIDE, Clinical endpoint, scleroderma, 030212 general & internal medicine, Enzyme Inhibitors, 11 Medical and Health Sciences, lung diseases, Lung Diseases, Interstitial -- drug therapy -- etiology -- physiopathology, 10051 Rheumatology Clinic and Institute of Physical Medicine, General Medicine, respiratory system, Sciences bio-médicales et agricoles, Middle Aged, Protein-Tyrosine Kinases, MANIFESTATIONS, Disease Progression, Nintedanib, Female, TYROSINE KINASE INHIBITOR, Life Sciences & Biomedicine, CLINICAL-TRIALS, Adult, Diarrhea, medicine.medical_specialty, FIBROBLASTS, 610 Medicine & health, Placebo, administration, behavioral disciplines and activities, 03 medical and health sciences, FEV1/FVC ratio, Medicine, General & Internal, Double-Blind Method, Internal medicine, General & Internal Medicine, Enzyme Inhibitors -- adverse effects -- therapeutic use, SCORE, medicine, Humans, Indoles -- adverse effects -- therapeutic use, Scleroderma, Systemic -- complications -- drug therapy, Science & Technology, Scleroderma, Systemic, Protein-Tyrosine Kinases -- antagonists & inhibitors, business.industry, MORTALITY, interstitial, PULMONARY-FUNCTION, systemic, STANDARDIZATION, medicine.disease, EFFICACY, respiratory tract diseases, body regions, chemistry, adult, diarrhea, disease progression, double-blind method, enzyme inhibitors, female, humans, indoles, lung diseases, interstitial, male, middle aged, protein-tyrosine kinases, scleroderma, systemic, vital capacity, business, Lung Diseases, Interstitial, Diarrhea -- chemically induced
Abstract

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD., info:eu-repo/semantics/published

Published
2019

12. 103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)

Author

Andric, Z.G., primary, Gálffy, G., additional, Dols, M. Cobo, additional, Szima, B., additional, Stojanovic, G., additional, Petrovic, M.D., additional, Font, E. Felip, additional, Baz, D. Vicente, additional, Aix, S. Ponce, additional, Juan-Vidal, O., additional, Tehenes, S., additional, Szalai, Z., additional, Losonczy, G., additional, Blanco, A. Calles, additional, Bernabe, R., additional, Duecker, K., additional, Zhou, D., additional, Schroeder, A., additional, Guezel, G., additional, and Ciardiello, F., additional

Published
2021
Full Text
View/download PDF

13. P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN

Author

Reinmuth, N., primary, Garassino, M.C., additional, Trukhin, D., additional, Hochmair, M.J., additional, Özgüroğlu, M., additional, Havel, L., additional, Goldman, J., additional, Chen, Y., additional, Losonczy, G., additional, Spinnato, F., additional, Conev, N., additional, Bar, J., additional, Broadhurst, H., additional, Byrne, N., additional, Jiang, H., additional, and Paz-Ares, L., additional

Published
2021
Full Text
View/download PDF

14. OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer

Author

Reck, M., primary, Horn, L., additional, Mok, T.S.K., additional, Mansfield, A., additional, De Boer, R., additional, Losonczy, G., additional, Sugawara, S., additional, Dziadziuszko, R., additional, Krzakowski, M., additional, Smolin, A., additional, Hochmair, M., additional, Garassino, M., additional, Castro, G., additional, Bischoff, H., additional, Cardona, A., additional, Morris, S., additional, and Liu, S., additional

Published
2021
Full Text
View/download PDF

18. 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer

Author

Liu, S.V., primary, Horn, L., additional, Mok, T., additional, Mansfield, A., additional, De Boer, R., additional, Losonczy, G., additional, Sugawara, S., additional, Dziadziuszko, R., additional, Krzakowski, M., additional, Smolin, A., additional, Hochmair, M.J., additional, Garassino, M.C., additional, Lam, S., additional, McCleland, M., additional, Cardona, A., additional, Morris, S., additional, and Reck, M., additional

Published
2020
Full Text
View/download PDF

20. CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC)

Author

Reinmuth, N, additional, Paz-Ares, L, additional, Chen, Y, additional, Hotta, K, additional, Trukhin, D, additional, Statsenko, G, additional, Hochmair, MJ, additional, Özgüroğlu, M, additional, Ho Li, J, additional, Voitko, O, additional, Poltoratskiy, A, additional, Ponce, S, additional, Verderame, F, additional, Havel, L, additional, Bondarenko, I, additional, Kazarnowicz, A, additional, Losonczy, G, additional, Conev, NV, additional, Armstrong, J, additional, Byrne, N, additional, Shire, N, additional, Jiang, H, additional, Goldman, J, additional, and Alt, J, additional

Published
2020
Full Text
View/download PDF

22. LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

Author

Özgüroğlu, M., primary, Goldman, J.W., additional, Reinmuth, N., additional, Chen, Y., additional, Dvorkin, M., additional, Trukhin, D., additional, Statsenko, G., additional, Hotta, K., additional, Ji, J.H., additional, Hochmair, M.J., additional, Voitko, O., additional, Havel, L., additional, Poltoratskiy, A., additional, Losonczy, G., additional, Verderame, F., additional, Thomas, M., additional, Zheng, Y., additional, Lloyd, A., additional, Jiang, H., additional, and Paz-Ares, L., additional

Published
2019
Full Text
View/download PDF

25. Gestational resistance to the pulmonary vasoconstrictor effect of the TxA2 mimetic U-46619: possible mechanism

Author

Losonczy, G., Brown, G., Mucha, I., Klocke, R., Muller, V., Merkely, B., Tornoci, L., Rosivall, L., and Venuto, R.

Subjects
Thromboxanes -- Physiological aspects, Pulmonary hypertension -- Physiological aspects, Pregnancy -- Physiological aspects, Biological sciences
Abstract

The effects of rabbit gestation on the pulmonary vascular pressor effects of U-46619 and downregulation of the thromboxane A2 receptors were analyzed in mechanically ventilated non-pregnant rabbits. Administration of U-46619 in mechanically ventilated non-pregnant rabbits stimulated vascular tone which were blunted late in pregnancy. Furthermore, the attenuation of pulmonary vascular response to the thromboxane analog protected the rabbits from the CO- and mean systemic arterial pressure-reducing effects of the compound.

Published
1997

29. PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Author

Paz-Ares, L., primary, Goldman, J.W., additional, Garassino, M.C., additional, Dvorkin, M., additional, Trukhin, D., additional, Statsenko, G., additional, Hotta, K., additional, Ji, J.H., additional, Hochmair, M.J., additional, Voitko, O., additional, Havel, L., additional, Poltoratskiy, A., additional, Losonczy, G., additional, Reinmuth, N., additional, Shrestha, Y., additional, Patel, N., additional, Mann, H., additional, Jiang, H., additional, Özgüroğlu, M., additional, and Chen, Y., additional

Published
2019
Full Text
View/download PDF

30. PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

Author

Paz-Ares, L., primary, Chen, Y., additional, Reinmuth, N., additional, Hotta, K., additional, Trukhin, D., additional, Statsenko, G., additional, Hochmair, M.J., additional, Özgüroğlu, M., additional, Ji, J.H., additional, Voitko, O., additional, Poltoratskiy, A., additional, Ponce, S., additional, Verderame, F., additional, Havel, L., additional, Bondarenko, I., additional, Kazarnowicz, A., additional, Losonczy, G., additional, Conev, N.V., additional, Armstrong, J., additional, Byrne, N., additional, Shire, N., additional, Jiang, H., additional, and Goldman, J., additional

Published
2019
Full Text
View/download PDF

31. PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC

Author

Liu, S., primary, Mansfield, A., additional, Szczesna, A., additional, Havel, L., additional, Krzakowski, M., additional, Hochmair, M., additional, Huemer, F., additional, Losonczy, G., additional, Johnson, M., additional, Nishio, M., additional, Reck, M., additional, Mok, T., additional, Lam, S., additional, Shames, D., additional, Liu, J., additional, Ding, B., additional, Kabbinavar, F., additional, Lin, W., additional, Sandler, A., additional, and Horn, L., additional

Published
2018
Full Text
View/download PDF

32. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

Author

Gerber, D.E., primary, Horn, L., additional, Boyer, M., additional, Sanborn, R., additional, Natale, R., additional, Palmero, R., additional, Bidoli, P., additional, Bondarenko, I., additional, Germonpre, P., additional, Ghizdavescu, D., additional, Kotsakis, A., additional, Lena, H., additional, Losonczy, G., additional, Park, K., additional, Su, W -C, additional, Tang, M., additional, Lai, J., additional, Kallinteris, N.L., additional, Shan, J.S., additional, Reck, M., additional, and Spigel, D.R., additional

Published
2018
Full Text
View/download PDF

34. MA 10.05 Improved Outcome for Immune Checkpoint Inhibitors (ICI) in Patients Previously Treated with Bavituximab in the SUNRISE Trial

Author

Boyer, M., primary, Spigel, D., additional, Mainwaring, P., additional, Lena, H., additional, Mccleod, M., additional, Losonczy, G., additional, Sanborn, R., additional, Natale, R., additional, Tang, M., additional, Lai, J., additional, Kallinteris, N., additional, Shan, J., additional, and Gerber, D., additional

Published
2017
Full Text
View/download PDF

35. Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer

Author

Palmero, R., primary, Bidoli, P., additional, Bondarenko, I.M., additional, Boyer, M., additional, Germonpre, P., additional, Ghizdavescu, D., additional, Kotsakis, A., additional, Lena, H., additional, Losonczy, G., additional, Park, K., additional, Reck, M., additional, Su, W.-C., additional, Kallinteris, N., additional, Tang, M., additional, Lai, J., additional, Shan, J., additional, and Spigel, D.R., additional

Published
2017
Full Text
View/download PDF

38. Clinical relevance is associated with allergen-specific wheal size in skin prick testing

Author

Haahtela, T. Burbach, G.J. Bachert, C. Bindslev-Jensen, C. Bonini, S. Bousquet, J. Bousquet-Rouanet, L. Bousquet, P.J. Bresciani, M. Bruno, A. Canonica, G.W. Darsow, U. Demoly, P. Durham, S.R. Fokkens, W.J. Giavi, S. Gjomarkaj, M. Gramiccioni, C. Kowalski, M.L. Losonczy, G. Orosz, M. Papadopoulos, N.G. Stingl, G. Todo-Bom, A. von Mutius, E. Köhli, A. Wöhrl, S. Järvenpää, S. Kautiainen, H. Petman, L. Selroos, O. Zuberbier, T. Heinzerling, L.M.

Subjects
immune system diseases, respiratory tract diseases
Abstract

Background: Within a large prospective study, the Global Asthma and Allergy European Network (GA2LEN) has collected skin prick test (SPT) data throughout Europe to make recommendations for SPT in clinical settings. Objective: To improve clinical interpretation of SPT results for inhalant allergens by providing quantitative decision points. Methods: The GA2LEN SPT study with 3068 valid data sets was used to investigate the relationship between SPT results and patient-reported clinical relevance for each of the 18 inhalant allergens as well as SPT wheal size and physician-diagnosed allergy (rhinitis, asthma, atopic dermatitis, food allergy). The effects of age, gender, and geographical area on SPT results were assessed. For each allergen, the wheal size in mm with an 80% positive predictive value (PPV) for being clinically relevant was calculated. Results: Depending on the allergen, from 40% (blatella) to 87-89% (grass, mites) of the positive SPT reactions (wheal size ≥ 3 mm) were associated with patient-reported clinical symptoms when exposed to the respective allergen. The risk of allergic symptoms increased significantly with larger wheal sizes for 17 of the 18 allergens tested. Children with positive SPT reactions had a smaller risk of sensitizations being clinically relevant compared with adults. The 80% PPV varied from 3 to 10 mm depending on the allergen. Conclusion: These 'reading keys' for 18 inhalant allergens can help interpret SPT results with respect to their clinical significance. A SPT form with the standard allergens including mm decision points for each allergen is offered for clinical use. © 2013 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.

Published
2014

39. Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer

Author

Spigel, D.R., primary, Bondarenko, I., additional, Losonczy, G., additional, Mezger, J., additional, Kalofonos, H., additional, Reck, M., additional, Palmero, R., additional, Jang, T., additional, Natale, R., additional, Sanborn, R.E., additional, Lai, J., additional, Kallinteris, N., additional, Tang, M., additional, Shan, J., additional, and Gerber, D., additional

Published
2016
Full Text
View/download PDF

41. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial

Author

Thatcher, N, Hirsch, F, Luft, A, Szczesna, A, Ciuleanu, T, Dediu, M, Ramlau, R, Galiulin, R, Bálint, B, Losonczy, G, Kazarnowicz, A, Park, K, Schumann, C, Reck, M, Depenbrock, H, Nanda, S, Kruljac-Letunic, A, Kurek, R, Paz-Ares, L, Socinski, M, Bidoli, P, Hirsch, FR, Luft, AV, Ciuleanu, TE, Galiulin, RK, Socinski, MA, Thatcher, N, Hirsch, F, Luft, A, Szczesna, A, Ciuleanu, T, Dediu, M, Ramlau, R, Galiulin, R, Bálint, B, Losonczy, G, Kazarnowicz, A, Park, K, Schumann, C, Reck, M, Depenbrock, H, Nanda, S, Kruljac-Letunic, A, Kurek, R, Paz-Ares, L, Socinski, M, Bidoli, P, Hirsch, FR, Luft, AV, Ciuleanu, TE, Galiulin, RK, and Socinski, MA

Abstract

Background: Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous non-small-cell lung cancer. Methods: We did this open-label, randomised phase 3 study at 184 investigative sites in 26 countries. Patients aged 18 years or older with histologically or cytologically confirmed stage IV squamous non-small-cell lung cancer, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and adequate organ function and who had not received previous chemotherapy for their disease were eligible for inclusion. Enrolled patients were randomly assigned centrally 1:1 to a maximum of six 3-week cycles of gemcitabine and cisplastin chemotherapy with or without necitumumab according to a block randomisation scheme (block size of four) by a telephone-based interactive voice response system or interactive web response system. Chemotherapy was gemcitabine 1250 mg/m2 administered intravenously over 30 min on days 1 and 8 of a 3-week cycle and cisplatin 75 mg/m2 administered intravenously over 120 min on day 1 of a 3-week cycle. Necitumumab 800 mg, administered intravenously over a minimum of 50 min on days 1 and 8, was continued after the end of chemotherapy until disease progression or intolerable toxic side-effects occurred. Randomisation was stratified by ECOG performance status and geographical region. Neither physicians nor patients were masked to group assignment because of the expected occurrence of acne-like rash-a class effect of EGFR antibodies-that would have unmasked most patients and investigators to treatment. The primary endpoint was overall survival, analysed by intention to treat. We report the final clinical analysis. This study is registered with ClinicalTrials.gov, number NCT00981058. Findings: Between Jan 7, 2010, and Feb 22, 2012, we

Published
2015

44. TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results

Author

Quoix, E., primary, Losonczy, G., additional, Forget, F., additional, Chouaid, C., additional, Papai, Z., additional, Gervais, R., additional, Ottensmeier, C., additional, Szczesna, A., additional, Kazarnowicz, A., additional, Beck, J.T., additional, Westeel, V., additional, Vanderheyde, K., additional, Lacoste, G., additional, Bastien, B., additional, Halluard, C., additional, Marchand, S., additional, Limacher, J.M., additional, and Léna, H., additional

Published
2014
Full Text
View/download PDF

45. 1364P - Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer

Author

Palmero, R., Bidoli, P., Bondarenko, I.M., Boyer, M., Germonpre, P., Ghizdavescu, D., Kotsakis, A., Lena, H., Losonczy, G., Park, K., Reck, M., Su, W.-C., Kallinteris, N., Tang, M., Lai, J., Shan, J., and Spigel, D.R.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results